Symbicort
provides a rapid and sustained improvement in lung function
(Calverley et al, 2003 and Szafranski et al, 2003).
Calverley et al, 2003 showed that Symbicort
maintained improvements in post-dose FEV1 in the 12 months
following treatment intensification with prednisolone and inhaled
formoterol. In contrast, the FEV1 declined after this
treatment intensification period with all other treatments
(budesonide alone, formoterol alone, placebo).
FEV1 measured at clinical visits
Symbicort
was also associated with higher morning PEF compared with budesonide
alone, formoterol alone and placebo.
Symbicort improves morning PEF
|
